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Novel Emulsion Base for Vaginal Yeast Infection with Half Drug Concentration
Rigved Nagarkar1*, Manan Patel1,2, Almas Babar1
ABSTRACT
The dissolution of the drug in the vaginal cavity strongly influences the efficacy of the product due to insufficient 
moisture at the vaginal site. This study was undertaken to develop semi-solid dosage forms of miconazole nitrate to 
optimize its release. Formulations containing miconazole nitrate at 2% were developed using hypromellose gel, non-
ionic emulsion, and cationic emulsion. The effect of penetration enhancers such as propylene glycol, dimethyl sulfoxide 
(DMSO), and diethylene glycol monoethyl ether at various concentrations was studied. Diffusion studies were carried 
out to evaluate the drug release and compared it against a commercial product. Formulation with the highest drug release 
was further evaluated at half (1%) drug concentration. Formulation with reduced drug levels along with the commercial 
product was evaluated for drug release for an extended time using human cadaver skin. The general order of average 
cumulative drug release from three bases was observed to be cationic emulsion > hydroxypropyl methylcellulose >non-
ionic emulsion. Among all samples, the cationic emulsion with 5% DMSO gave a maximum drug release of 7.27 ± 0.2 
mg/cm2 with a flux of 0.70 mg/cm2/min compared to only 3.09 ± 0.1 mg/cm2 drug release with 0.51 mg/cm2/min flux 
for brand product. The average cumulative drug release for formulation with half (1%) drug and brand (2% drug) over a 
period of 12 h through human cadaver skin was observed to be 8.28 ± 0.9 mg/cm2 and 8.71 ± 0.9 mg/cm2, respectively. 
This observation was in conformance with the in vitro antifungal studies showing an equivalent zone of inhibition.
Keywords: Cationic emulsion, Drug release, Dimethylsulfoxide, In vitro antifungal study.
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INTRODUCTION
In recent years, the pharmaceutical industry is investing 
a maximum of their R&D efforts into the development of 
delivery systems, rather than pouring millions of dollars 
in inventing new molecules. This approach of new drug 
delivery systems is a potential pathway through which 
companies can optimize drug-formulation systems to 
have a maximum therapeutic benefit with minimum 
toxic effects. To achieve this goal, the area in focus is the 
improvement of formulation characteristics to improve 
or enhance its clinical efficacy. Drugs are delivered and 
marketed in various drug delivery systems, namely, 
oral, parenteral, sublingual, and topical. Topical drug 
delivery has taken a noticeable growth in recent years 
due to its obvious advantages such as avoiding first-pass 
metabolism, patient compliance, and others.[1] Topical 
dosage form includes creams, ointments, gel, solution, 
lotion, and spray.[2] Creams are mostly emulsion-based 
products which are either water in oil or oil in water type. 
Emulsions are a mixture of the oil phase and water phase 
stabilized by surfactant(s).[3] The nature and concentration 
of surfactants play an important role in the emulsion 
type and stability. For instance, a surfactant with a high 
hydrophilic-lipophilic balance (HLB) will form an oil-
in-water emulsion, whereas a low HLB value surfactant 
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will form a water in oil emulsion. Surfactants, based on 
the charge on the molecule, can be classified as anionic, 
cationic, and non-ionic. Permeation enhancers are a class 
of substances which stimulate the absorption of the drug 
through the skin.[4] Permeation enhancers or permeability 
enhancers increase the absorption of the drug by two 
different techniques. Some group of enhancers increases 
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the solubility of the drug, therefore, increasing the 
absorption. The second type of enhancers alters the skin 
structure permanently or temporarily, thus increasing the 
flux of drug across the skin.[5]
Topical drug delivery includes two basic types 
of products, one which is externally applied the second 
type is internally applied to the mucous membrane.[6,7] 
Recently, mucosal delivery is gaining a big popularity 
as drug delivery route. Specifically, vaginal delivery is 
attracting a lot of interest from the scientific community. 
Vagina is S-shaped with its folded walls.[8-10] The vaginal 
wall consists of a plethora of blood vessels which can be 
used for systemic delivery.[11] Vaginal drug delivery has 
been normally used for local administration of drugs 
rather than systemic route. There are still some challenges 
faced with the vaginal delivery of drugs. Delivery of drugs 
in the vagina depends not only on the formulation factors 
but also on patient factors such as humidity, secretions, 
and pH. Any biological or formulation factor affecting 
these parameters can affect drug absorption.
A vaginal yeast infection is inflammation of the 
vagina, which causes vaginal irritation, intense itchiness, 
and vaginal discharge.[12] A vaginal yeast infection affects 
the vagina and the tissues at the opening to vagina (vulva). 
Candida and the many other germs that normally live 
in the vagina keep each other in balance.[13] However, 
sometimes, the number of Candida albicans increases 
due to the external and physiological factors, leading to 
a yeast infection. Miconazole is the drug of choice for 
such infections. In addition to its antifungal and anti-
parasitic action, it also has some antibacterial properties. 
In vitro studies suggest that it inhibits ergosterol synthesis. 
Ergosterol is a critical component in the fungal cell 
membrane.[14]
A drug to show its activity needs to be in a molecular 
form; in other words, needs to be soluble. It was extending 
this concept for a topical product applied onto the skin, 
drug which in the dissolved state will show its effect while 
undissolved drug would remain on the skin. This general 
principle was taken into consideration to enhance the drug 
solubility in the vehicle to provide optimum release of 
the drug. An increase in solubility was also accompanied 
by penetration enhancer ability to further promote drug 
absorption. Formulation with enhanced drug release due 
to the double impact of solubility and penetration enhancer 
was evaluated for efficacy at half the drug level.
MATERIALS AND METHODS
Miconazole nitrate was purchased from Letco Medical 
(Decatur, AL), Hydroxypropyl methylcellulose 
hydroxypropyl methylcellulose (HPMC) (Methocel® 
K 100M premium) from Colorcon (Mumbai, India), 
Catemol WPC from Phoenix Chemicals Inc (Somerville, 
NJ), Cetyl alcohol from Amend Drugs and Chemicals 
(New Jersey), Glyceryl monostearate (SE) from Hallstar 
(Chicago, IL), 95% Ethanol from Pharmaco-Aaper 
(Toronto, Canada), dimethyl sulfoxide (DMSO) from 
Fagron (St. Paul, MN), Mineral Oil, Polysorbate 80, 
propylene glycol (PG), diethylene glycol monoethyl ether 
(DGME), Dextrose, Peptone, Agar and Cellulose Spectra/
pro seven dialysis membrane from Spectrum Chemicals 
and Lab Products (Henderson, NV), and Human Cadaver 
Skin was obtained from The New York Fire Fighter Skin 
Bank (New York, NY).
Preparation of Standard Curve for Miconazole 
Nitrate
A 100 mg of miconazole nitrate was dissolved in 100 mL 
of 95% ethanol. This was labeled as “stock solution A.” 
10 mL of “stock solution A” was taken in another 100 mL 
volumetric flask. The volume was made up to 100 mL, 
with 95% ethanol. This solution was labeled as “stock 
solution B.” From “stock solution B,” 2 mL, 4 mL, 6 mL, 
8 mL, and 10 mL solutions were withdrawn into different 
100 mL volumetric flasks. Volume was made up to 100 mL 
using deionized water. Hence, the resulting concentrations 
in the flasks were 2 µg/mL, 4 µg/mL, 6 µg mL, 8 µg mL, 
and 10 µg/mL, respectively.[15] Sample with 10 µg/mL 
concentration was scanned using an ultraviolet (UV) 
spectrophotometer primarily for determining the 
maximum absorption (ƛ
max)
 of the drug. Miconazole 
nitrate showed a peak at 271 nm, which was similar to the 
literature value of maximum absorbance at 272 nm.[16] A 
calibration curve was established using miconazole nitrate 
dilutions. A linear regression was performed, and the 
equation obtained was used to calculate the concentration 
of unknown samples.
Preparation of Formulation Bases
Non-ionic gel base
The required amount of HPMC was thoroughly 
dispersed in one-third of the required total amount of 
water at a temperature of 80–90°C. The agitation was 
continued until all the particles were wetted, and a 
consistent dispersion was obtained. The remainder of 
the water was added as cold water while agitating until 
a homogenous solution was obtained.[17] The solution 
was cooled down at room temperature. Agitation was 
continued until room temperature was reached to form a 
uniform, transparent gel matrix. The composition of the 
gel is shown in Table 1.
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Preparation of samples
The required amount of miconazole nitrate [Table 2] 
was dissolved in DMSO at pre-determined levels (5%, 
10%, and 15% w/w). The required amount of deionized 
water [Table 2] was added to the drug-DMSO mixture. 
This mixture was then incorporated into the gel base 
with optimum mixing with a Lightnin mixer (Palo Lab 
Supplies, New York) to ensure the drug-penetration 
enhancer mixture is uniformly distributed throughout the 
gel base. The same process was used to formulate samples 
using different penetration enhancers (PG and DGME) at 
the same levels as DMSO [Table 2].
Non-ionic emulsion base
A mixture of the calculated amount of oil phase ingredients 
[Table 3], namely, mineral oil, cetyl alcohol, and glyceryl 
monostearate self-emulsifying (GMS-SE) was melted 
in a beaker by heating at 75–80°C. Simultaneously, in 
second beaker water phase ingredients, i.e., glycerin, 
polysorbate 80, and water were heated while mixing with 
Lightnin’ mixer at 75–80°C. Oil phase ingredients were 
added to the water phase ingredients (stirring constantly) 
at the temperature of 75–80°C. Stirring was continued for 
10–15 min at this temperature. The emulsion was then 
cooled down at room temperature while stirring.[18]
Preparation of samples
The samples were prepared similar to the gel base, where the 
required amount of miconazole nitrate [Table 4] was dissolved 
in DMSO, PG, and DGME separately at pre-determined 
levels (5%, 10%, and 15% w/w) with the application of 
heat (40–45°C). The calculated amount of water [Table 4] 
was added to the drug-enhancer mixture, which was then 
incorporated into the non-ionic emulsion base with mixing.
Cationic emulsion base
A mixture of the calculated amount of oil phase ingredients 
[Table 5], namely, mineral oil, cetyl alcohol, and glyceryl 
monostearate was melted in a beaker by heating at 
75–80°C. Simultaneously, in second beaker water phase 
ingredients, i.e., glycerin, Catemol WPC, polysorbate 80, 
and water were heated while mixing with Lightnin’ mixer 
at 75–80°C. Oil phase ingredients were added to the water 
phase ingredients (stirring constantly) at the temperature 
of 75–80°C. Stirring was continued for 10–15 min at this 
temperature. The emulsion was then cooled down to room 
temperature while stirring.
Preparation of samples
The sample preparation method similar to the previously 
mentioned gel and emulsion bases was followed, where 
required amount of miconazole nitrate [Table 6] was 
dissolved in DMSO, PG, and DGME separately at pre-
determined levels (5%, 10%, and 15% w/w) with the 
application of heat (40–45°C). The calculated amount of 
water [Table 6] was added to the drug-enhancer mixture, 
which was then incorporated into the cationic cream base 
with mixing.
In vitro Diffusion Studies
Using cellulose membrane
The delivery of drugs through the skin for local, targeted, 
or systemic delivery can be measured by in vitro and in vivo 
techniques.[19] Frequently, this has been done by in vitro 
technique because of the simplicity of the experimental 
design and conditions [Figure 1].
One-gram sample was placed in the donor 
compartment over the cellulose membrane and spread 
uniformly without entrapment of air bubbles.[20] The 
Table 1: Composition of non-ionic gel base
Ingredients Grams
Hydroxypropyl methylcellulose 2.0
Purified water 78.0
Total 80.0
Table 2: Formulations using non-ionic gel base
Ingredients Formulations (grams)
Control DMSO Propylene glycol DGME
0% 5% 10% 15% 5% 10% 15% 5% 10% 15%
Hydroxypropyl methylcellulose gel base 80 80 80 80 80 80 80 80 80 80
Miconazole nitrate 2 2 2 2 2 2 2 2 2 2
DMSO - 5 10 15 - - - - - -
Propylene glycol - - - - 5 10 15 - - -
DGME - - - - - - - 5 10 15
Purified water q.s. 100 100 100 100 100 100 100 100 100 100
DMSO: Dimethyl sulfoxide, DGME: Diethylene glycol monoethyl ether
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receptor compartment has 13 mL of deionized water, 
which served as the diffusion medium and was stirred 
using a magnetic stirrer at a speed of 600. The limited 
solubility of miconazole nitrate in deionized water avoids 
dose dumping and will ensure constant release across 
the membrane. High, stirring speed helps in preventing 
any formation of any diffusion layer barrier resistance 
for the permeation of drugs. Aliquots (0.5 mL) from the 
receptor medium were withdrawn through the sampling 
port of the receptor compartment at pre-determined time 
intervals and replaced with fresh medium (0.5 mL) at each 
time interval. Collected samples were analyzed using 
a UV spectrophotometer at 271 nm. Each experiment 
was performed in triplicate for each formulation. Brand 
formulation Monistat (2%) was used as a control.
Optimizing the drug quantity in the base of choice
The formulation with the highest release was further 
evaluated for the optimization of drug concentration. The 
concentration of drug was reduced to half, i.e., 1%. The 
formulation will be denoted as Formulation IV.
Extended release studies using a cellulose membrane
The selected formulation (Formulation IV) was evaluated 
for drug release using cellulose membrane as a diffusion 
barrier against brand formulation for extended time 
period (12 h).
Using human cadaver skin
Full-thickness dermatome human cadaver skin from the 
right posterior leg of a male subject from “The New York 
Fire Fighters Skin Bank” was taken as a membrane. The 
cadaver skin was immersed in 100 mL of normal saline 
solution at room temperature for about 12 h before the 
experimentation. The skin was then grafted into pieces 
of size of approximately 2 cm2. The integrity of the skin 
was checked by visual inspection to ensure the intactness 
of the skin and the presence of holes or imperfections (if 
any).[21] After thawing, the cadaver skin was mounted in 
between donor and receptor compartment. The skin was 
placed on the receiver chamber with stratum corneum 
facing toward the donor compartment. The experimental 
setup was the same as studies with a cellulose membrane. 
The experiments were performed in triplicate for each 
formulation.
In vitro Antifungal Activity
The antifungal efficacy studies were carried out using 
Sabouraud’s dextrose agar[22] [Table 7] to ascertain the 
Table 3: Composition of non-ionic emulsion base
Ingredients Grams
Mineral oil 4.00
Cetyl alcohol 2.00
Glyceryl monostearate self-emulsifying 4.00
Glycerin 5.00
Polysorbate 80 2.00
Water q.s. 80.00
Table 4: Formulations using non-ionic emulsion base
Ingredients Formulations (grams)
Control DMSO Propylene glycol DGME
0% 5% 10% 15% 5% 10% 15% 5% 10% 15%
Non-ionic emulsion base 80 80 80 80 80 80 80 80 80 80
Miconazole nitrate 2 2 2 2 2 2 2 2 2 2
DMSO - 5 10 15 - - - - - -
Propylene glycol - - - - 5 10 15 - - -
DGME - - - - - - - 5 10 15
Purified water q.s 100 100 100 100 100 100 100 100 100 100
DMSO: Dimethyl sulfoxide, DGME: Diethylene glycol monoethyl ether
Figure 1: Franz cell diffusion
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biological activity of the lead formulation of miconazole 
nitrate in comparison with the brand formulation against 
yeast micro-organism.
Cup plate method[23]
The Sabouraud’s dextrose agar medium was taken into 
a 250 ml conical flask and was dissolved in 100 ml of 
distilled water. The pH of the medium was adjusted to 
5.6, and it was sterilized in an autoclave at 121°C for 
20 min. After the sterilization process, the medium was 
cooled at 40–45°C. A layer of the medium (~20 ml) was 
then poured into a sterilized Petri dish to give a depth 
of 3–4 mm. Cultures of yeast micro-organisms were 
dispersed in freshly prepared in yeast growth medium, 
and 0.5 ml of this was added and spread evenly on the 
solidified agar medium. The samples of miconazole nitrate 
creams – Formulation IV and Brand (0.1 g each) were 
carefully placed in the center of separate Petri dish and 
were incubated at room temperature for 48 h. The zone of 
inhibition was measured for both formulations.
RESULTS
Preparation of Standard Curve
A standard curve is plotted with absorbance on the Y-axis 
and concentration of the standard in µg/mL on X-axis, as 
shown in Figure 2.
The standard curve for miconazole nitrate depicted 
a linear relationship and regression analysis with a very 
high correlation coefficient of 0.99.
In vitro Release Data
The drug release of miconazole nitrate from various 
semi-solid bases over a period of 2 h is shown in Figure 3. 
As per the data shown below, the overall order of release 
from the selected bases is seen to follow the order as 
follows:
Table 5: Composition of cationic emulsion base
Ingredients Grams
Mineral oil 6.00
Cetyl Alcohol 1.50
Glyceryl Monostearate 4.00
Catemol WPC 0.80
Glycerin 5.00
Polysorbate 80 1.00
Water q.s. 80.00
Table 6: Formulations using cationic emulsion base
Ingredients Formulations (grams)
Control DMSO Propylene glycol DGME
0% 5% 10% 15% 5% 10% 15% 5% 10% 15%
Cationic emulsion base 80 80 80 80 80 80 80 80 80 80
Miconazole nitrate 2 2 2 2 2 2 2 2 2 2
DMSO - 5 10 15 - - - - - -
Propylene glycol - - - - 5 10 15 - - -
DGME - - - - - - - 5 10 15
Purified water q.s. 100 100 100 100 100 100 100 100 100 100
DMSO: Dimethyl sulfoxide, DGME: Diethylene glycol monoethyl ether
Figure 2: Standard curve for miconazole nitrate 
Figure 3: Average cumulative drug release from different bases
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Cationic emulsion system > Gel base system > Non-
ionic emulsion system.
The average cumulative drug release from 
cationic emulsion, gel base, and non-ionic emulsion is 
observed to be 5.29 ± 0.3 mg/cm2, 4.46 ± 0.1 mg/cm2, 
and 2.36 ± 0.6 mg/cm2, respectively, for a period of 2 h 
through a cellulose membrane, while brand formulation 
(Monistat® 2%) showed 3.10 ± 0.4 mg/cm2 [Figure 3].
HPMC Gel Base
The in vitro release of drugs from HPMC gel base in 
the presence of penetration enhancers DMSO, PG, and 
DGME is shown in Figures 4-6, respectively.
Non-ionic emulsion based cream
The in vitro release of drug from non-ionic emulsion base 
in the presence of penetration enhancers DMSO, PG, and 
DGME is shown in Figures 7-9, respectively.
Table 7: Composition of Sabouraud’s dextrose agar
Ingredients (%w/w)
Dextrose 4.00
Peptone 1.00
Agar 2.00
Distilled water (q.s) 100.00
Figure 4: Average cumulative drug release from hydroxypropyl 
methylcellulose gel base with dimethyl sulfoxide
Figure 5: Average cumulative drug release from hydroxypropyl 
methylcellulose gel base with propylene glycol
Figure 6: Average cumulative drug release from hydroxypropyl 
methylcellulose gel base with diethylene glycol monoethyl ether
Figure 7: Average cumulative drug release from nonionic cream 
base with dimethyl sulfoxide
Figure 8: Average cumulative drug release from non-ionic cream 
base with propylene glycol
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Cationic emulsion based cream
The in vitro release of drug from cationic emulsion base 
in the presence of penetration enhancers DMSO, PG, and 
DGME is shown in Figures 10-12, respectively.
Optimizing the drug quantity in base of choice
Formulation IV with cationic emulsion with 5% DMSO 
(1% drug) showed an average cumulative drug release of 
3.87 ± 0.4 mg/cm2 [Figure 13].
Extended release studies using cellulose membrane
The average cumulative drug release after 12 h was found 
to be 8.58 ± 0.4mg/cm2 and 7.74 ± 0.3mg/cm2 for the 
brand and Formulation IV, respectively [Figure 14].
Figure 9: Average cumulative drug release from nonionic cream 
base with diethylene glycol monoethyl ether
Figure 10: Average cumulative drug release from cationic cream 
base with dimethyl sulfoxide
Figure 11: Average cumulative drug release from cationic cream 
base with propylene glycol
Figure 12: Average cumulative drug release from cationic cream 
base with diethylene glycol monoethyl ether
Figure 13: Average cumulative drug release from Formulation IV
Figure 14: Average cumulative drug release from Formulation IV 
versus brand on cellulose membrane
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In vitro release of miconazole nitrate using human 
cadaver skin
The average cumulative drug release after 12 h across a 
human cadaver skin for brand product and Formulation IV 
was found to be 8.71 ± 0.9 mg/cm2 and 8.28 ± 0.9 mg/cm2, 
respectively [Figure 15].
In vitro Antifungal Studies
The results for in vitro antifungal studies is shown in 
Figure 16a and shows 0 h incubation with no growth 
of fungus, while Figure 16b shows 48 h incubation 
with an equal zone of inhibition for both brand and 
Formulation IV.
DISCUSSION
The standard curve for miconazole nitrate depicted a 
linear relationship and regression analysis with a very 
high correlation coefficient of 0.99, which confirms 
that plot obeys Beer-Lamberts law.[24] A significant data 
are available on the spectrophotometric analysis of 
miconazole nitrate.[15,25] Some researchers have analyzed 
individual molecules while others have worked with a 
mixture of multiple molecules.[26-28] The standard curve 
of miconazole nitrate came out as expected with a linear 
relationship between concentration and absorbance.
Miconazole nitrate is a salt of weak base. The drug 
belongs to the Biopharmaceutics Classification System 
(BCS) Class II.[29,30] One of the ways to increase the drug 
release from a base for an insoluble/partially soluble active 
is to increase the solubility of the drug in the base. This 
theory is in accordance with Fick’s first law of diffusion, 
which states that drug diffusion is a function of the 
concentration gradient.[31] More the concentration gradient 
higher is the rate of drug diffusion. The concentration 
gradient is based on the amount of drug dissolved in 
the base, hence, available to diffuse. A wide range of 
techniques is available to increase drug solubilities such as 
salt formation,[32] particle size reduction,[33] polymorphs,[34] 
use of cosolvents, and pH changes.[35]
The pka of miconazole is 6.77.[36] Based on the 
Henderson-Hasselbach equation for salt of weak base 
(Miconazole Nitrate), lower the pH (acidic) higher will 
be the ionization state of miconazole, thus increasing 
its solubility. Release from different topical bases was 
evaluated, where the highest drug release was shown by 
cationic emulsion, followed by gel base and lastly non-
ionic emulsion. The term “cationic” and “non-ionic” 
emulsions were used to signify the nature of the surfactant 
used in the emulsions. N(Stearoyl Colaminoformyl Methyl) 
Pyridinium Chloride, commonly known as Catemol WPC, 
is a cationic surfactant used as an emulsifier. GMS-SE is 
a well-known non-ionic emulsifier used in many topical 
formulations.[17] Highest release was observed from 
cationic base when compared to other topical bases. It can 
be attributed to the higher solubility of miconazole nitrate in 
the cationic emulsion base. The pH of cationic emulsion is 
on the acidic side, mainly due to Catemol. Catemol shows a 
pH of 3.0 at 1% w/v solutions.[37] The least amount of drug 
release from non-ionic emulsion base could be attributed 
to the complex structure of emulsion. On the other hand, 
HPMC is known to swell. The swelling of HPMC occurs 
Figure 15: Average cumulative drug release from Formulation IV 
versus brand across human cadaver skin
Figure 16: (a and b) Antifungal plates before and after incubation
b
a
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by influx of surrounding water.[38] This influx can increase 
the solubility of miconazole nitrate as more solvent is now 
available for drugs; hence, a higher release for HPMC 
gel formulation is seen than non-ionic emulsion. Brand 
formulation Monistat® 7 uses cetyl and stearyl alcohols 
as emulsifier. These excipients are non-ionic in nature. 
Therefore, a release profile and average cumulative drug 
release are similar and closer to non-ionic emulsion.
A slightly higher release for Monistat® 7 was 
observed than a non-ionic emulsion. The higher release 
could be due to the presence of solubilizer PG and 
penetration enhancer isopropyl myristate. Penetration 
enhancers play a critical role in the diffusion process. 
Penetration enhancers are mainly divided into two 
categories depending on their mechanism of action. The 
first type is where the solubility of the active is increased, 
thus increasing its permeation, while second type of 
enhancers act reversibly or irreversibly on the skin, thus 
increase permeation of drug through the skin. PG, DMSO, 
and DGME were selected as penetration enhancers based 
on their ability to solubilize API and their mechanism of 
action on the skin. DMSO is used as penetration enhancer 
in formulations at concentrations as high as 15%.[17] 
DMSO interacts with intercellular lipids present in the 
stratum corneum. They form aprotic interactions, which 
cause a reversible alteration of lipids. This way it disrupts 
the barrier function of stratum corneum.[39] PG and DGME 
exert its mechanism of action as a penetration enhancer 
by dissolving lipids. This results in pore formation in the 
stratum corneum. The dissolution of skin lipids increases 
the cutaneous hydration.[40] In addition to their ability to 
disrupt the skin structure, they also increase the solubility 
of miconazole nitrate. Miconazole nitrate, as discussed 
earlier, is a BCS Class II drug with water solubility of 
26.3 µg/mL.[41] PG increases the solubility of miconazole 
nitrate significantly, as high as 44.38 mg/mL.[42] DMSO 
also has shown to increase the solubility of the drug at a 
staggering approximately 1000 times (25 mg/mL).[43]
An increase in drug release with the addition of 
penetration enhancer was expected due to the increased 
solubility of the miconazole nitrate in the formulations. 
This observation was accurate for all the formulations. 
Although, the drug release did not necessarily increase 
with an increase in the level of penetration enhancer. In 
fact, a reverse action was observed for prototypes with gel 
base with PG, non-ionic emulsion with PG, and non-ionic 
emulsion with DGME where the drug release decreased 
with an increase in the level of penetration enhancer. Some 
formulations showed an increase in drug release at high 
enhancer concentrations. Formulations such as gel base 
with DMSO and DGME showed increased drug release 
at 15% and 10% enhancer concentrations, respectively. 
While non-ionic emulsion with DMSO did not show any 
difference with increase in enhancer level, but the release 
was higher compared to enhancer free formulation. The 
important factors influencing the penetration of the drug 
into the skin are not only the concentration of drugs but 
also the partition coefficient between the membrane and 
the base. The partition coefficient reflects the affinity of 
the drug for the membrane with respect to its formulation 
base.[44] Therefore, as the solubility of the drug in the base 
in significantly increased by PG, DMSO, and DGME, 
miconazole nitrate’s relative affinity in the formulation 
base increases compared to the membrane. Therefore, we 
do not see an increase in the drug release with an increase 
in the concentration of penetration enhancers. The same 
theory could be applied to the cationic emulsion with 
DMSO and PG. The highest release was observed with 5% 
DMSO and 10% PG for the two prototypes, respectively.
Reducing the drug quantity showed the same release 
characteristics for cellulose membranes and human cadaver 
skin. The average cumulative drug release (mg/cm2) was 
found to be similar to the brand. This comparable release 
of drugs from 1% formulation to a 2% Monistat is due 
to the presence of penetration enhancer DMSO at 5% 
concentration and an optimum base providing an increased 
solubility into the base. This comparable release from 
in vitro diffusion studies on cadaver skin was coupled with 
in vitro antifungal studies. Miconazole Nitrate inhibits 
ergosterol synthesis. Ergosterol is a chemical in the fungal 
cell membrane, inhibition of which leads to ruptured cell 
wall causing fungal cell death.[45] When Monistat was 
compared against Formulation IV on a Petri dish, a same 
zone of inhibition was observed. This matches with the 
drug release data showing that an equal release and equal 
efficacy in vitro was observed with the half concentration 
of drug compared to the brand formulation.
CONCLUSION
The in vitro diffusion studies were designed to evaluate 
the release of miconazole nitrate from various bases, 
namely, HPMC gel base, non-ionic emulsion base and a 
cationic emulsion base. This proved to be a useful method 
in screening formulation for the relative availability of 
the active ingredient. The in vitro data obtained from 
the diffusion studies indicated a general rank order of 
miconazole nitrate from the bases as: Cationic Emulsion 
Base >HPMC gel base >Non-ionic Emulsion base. In 
addition, the effect of various additives such as DMSO, 
PG, and DGME at different concentrations, on drug 
release was evaluated. The highest drug release was 
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exhibited by the cationic emulsion system. The effect of 
penetration enhancers was also seen, where 5% DMSO 
showed the best effect on drug release. This formulation 
with best release was selected for optimizing the drug 
concentration and was evaluated for extended study of 12 
h through human cadaver skin. A comparable release was 
observed with the same zone of inhibitions with half drug 
level compared to the brand formulation. With an strong 
understanding of the nature of the molecule, its solubility 
characteristics, formulation base chemistry, it is possible 
to reduce the level of drug in an formulation without 
impacting its efficacy.
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